National aids incidence trends and the extent of zidovudine therapy in selected demographic and transmission groups

Philip S. Rosenberg, Mitchell H. Gail, Lewis K. Schräger, Sten H. Vermund, Terri Creagh-Kirk, Elizabeth B. Andrews, Warren Winkelstein, Michael Marmor, Don Des Jarlais, Robert J. Biggar, James J. Goedert

Research output: Contribution to journalArticle

Abstract

After mid-1987 fewer than the expected number of cases of AIDS were reported in the United States in some demographic and transmission groups but not in others. Gay men (regardless of intravenous drug use), adults with hemophilia, and transfusion recipients exhibited fewer cases than expected based on previously reliable models. These favorable trends could not be explained by assuming earlier cessation of human immunodeficiency virus (HIV) infection. Favorable AIDS incidence trends were not found in heterosexual intravenous drug users or in persons infected through heterosexual contact. White gay men from New York City, Los Angeles, and San Francisco experienced markedly favorable trends, whereas little change was observed for nonwhite gay men from nonurban areas. AIDS incidence trends were quantitatively consistent with the fraction of AIDS-free persons with severe immunodeficiency who received zidovudine in three cohorts. Gay men in San Francisco used zidovudine more frequently than did adults with hemophilia, while little was used by intravenous drug users in New York City. Data describing the initial national distribution of zidovudine (March 31-September 18, 1987) indicated relatively high use by patients with severe immunodeficiency in those groups, such as urban white gay men, that subsequently experienced fewer cases of AIDS than expected. Available data suggest that zidovudine, perhaps in combination with other therapies, has been one factor contributing to favorable AIDS incidence trends in some groups. Broader application of therapy might further retard the incidence of AIDS, especially in intravenous drug users, persons infected through heterosexual contact, minorities, women, and persons diagnosed outside major metropolitan areas.

Original languageEnglish (US)
Pages (from-to)392-401
Number of pages10
JournalJournal of Acquired Immune Deficiency Syndromes
Volume4
Issue number4
StatePublished - Jan 1 1991

Fingerprint

Zidovudine
Acquired Immunodeficiency Syndrome
Demography
Incidence
Heterosexuality
Drug Users
San Francisco
Hemophilia A
Therapeutics
Los Angeles
Virus Diseases
Sexual Minorities
HIV
Pharmaceutical Preparations

Keywords

  • Access to health care
  • AIDS incidence
  • Backcalculation
  • Human immunodeficiency virus
  • Zidovudine

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Rosenberg, P. S., Gail, M. H., Schräger, L. K., Vermund, S. H., Creagh-Kirk, T., Andrews, E. B., ... Goedert, J. J. (1991). National aids incidence trends and the extent of zidovudine therapy in selected demographic and transmission groups. Journal of Acquired Immune Deficiency Syndromes, 4(4), 392-401.

National aids incidence trends and the extent of zidovudine therapy in selected demographic and transmission groups. / Rosenberg, Philip S.; Gail, Mitchell H.; Schräger, Lewis K.; Vermund, Sten H.; Creagh-Kirk, Terri; Andrews, Elizabeth B.; Winkelstein, Warren; Marmor, Michael; Des Jarlais, Don; Biggar, Robert J.; Goedert, James J.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 4, No. 4, 01.01.1991, p. 392-401.

Research output: Contribution to journalArticle

Rosenberg, PS, Gail, MH, Schräger, LK, Vermund, SH, Creagh-Kirk, T, Andrews, EB, Winkelstein, W, Marmor, M, Des Jarlais, D, Biggar, RJ & Goedert, JJ 1991, 'National aids incidence trends and the extent of zidovudine therapy in selected demographic and transmission groups', Journal of Acquired Immune Deficiency Syndromes, vol. 4, no. 4, pp. 392-401.
Rosenberg PS, Gail MH, Schräger LK, Vermund SH, Creagh-Kirk T, Andrews EB et al. National aids incidence trends and the extent of zidovudine therapy in selected demographic and transmission groups. Journal of Acquired Immune Deficiency Syndromes. 1991 Jan 1;4(4):392-401.
Rosenberg, Philip S. ; Gail, Mitchell H. ; Schräger, Lewis K. ; Vermund, Sten H. ; Creagh-Kirk, Terri ; Andrews, Elizabeth B. ; Winkelstein, Warren ; Marmor, Michael ; Des Jarlais, Don ; Biggar, Robert J. ; Goedert, James J. / National aids incidence trends and the extent of zidovudine therapy in selected demographic and transmission groups. In: Journal of Acquired Immune Deficiency Syndromes. 1991 ; Vol. 4, No. 4. pp. 392-401.
@article{9b1f9256cb6242079530cdf051ade4b9,
title = "National aids incidence trends and the extent of zidovudine therapy in selected demographic and transmission groups",
abstract = "After mid-1987 fewer than the expected number of cases of AIDS were reported in the United States in some demographic and transmission groups but not in others. Gay men (regardless of intravenous drug use), adults with hemophilia, and transfusion recipients exhibited fewer cases than expected based on previously reliable models. These favorable trends could not be explained by assuming earlier cessation of human immunodeficiency virus (HIV) infection. Favorable AIDS incidence trends were not found in heterosexual intravenous drug users or in persons infected through heterosexual contact. White gay men from New York City, Los Angeles, and San Francisco experienced markedly favorable trends, whereas little change was observed for nonwhite gay men from nonurban areas. AIDS incidence trends were quantitatively consistent with the fraction of AIDS-free persons with severe immunodeficiency who received zidovudine in three cohorts. Gay men in San Francisco used zidovudine more frequently than did adults with hemophilia, while little was used by intravenous drug users in New York City. Data describing the initial national distribution of zidovudine (March 31-September 18, 1987) indicated relatively high use by patients with severe immunodeficiency in those groups, such as urban white gay men, that subsequently experienced fewer cases of AIDS than expected. Available data suggest that zidovudine, perhaps in combination with other therapies, has been one factor contributing to favorable AIDS incidence trends in some groups. Broader application of therapy might further retard the incidence of AIDS, especially in intravenous drug users, persons infected through heterosexual contact, minorities, women, and persons diagnosed outside major metropolitan areas.",
keywords = "Access to health care, AIDS incidence, Backcalculation, Human immunodeficiency virus, Zidovudine",
author = "Rosenberg, {Philip S.} and Gail, {Mitchell H.} and Schr{\"a}ger, {Lewis K.} and Vermund, {Sten H.} and Terri Creagh-Kirk and Andrews, {Elizabeth B.} and Warren Winkelstein and Michael Marmor and {Des Jarlais}, Don and Biggar, {Robert J.} and Goedert, {James J.}",
year = "1991",
month = "1",
day = "1",
language = "English (US)",
volume = "4",
pages = "392--401",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - National aids incidence trends and the extent of zidovudine therapy in selected demographic and transmission groups

AU - Rosenberg, Philip S.

AU - Gail, Mitchell H.

AU - Schräger, Lewis K.

AU - Vermund, Sten H.

AU - Creagh-Kirk, Terri

AU - Andrews, Elizabeth B.

AU - Winkelstein, Warren

AU - Marmor, Michael

AU - Des Jarlais, Don

AU - Biggar, Robert J.

AU - Goedert, James J.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - After mid-1987 fewer than the expected number of cases of AIDS were reported in the United States in some demographic and transmission groups but not in others. Gay men (regardless of intravenous drug use), adults with hemophilia, and transfusion recipients exhibited fewer cases than expected based on previously reliable models. These favorable trends could not be explained by assuming earlier cessation of human immunodeficiency virus (HIV) infection. Favorable AIDS incidence trends were not found in heterosexual intravenous drug users or in persons infected through heterosexual contact. White gay men from New York City, Los Angeles, and San Francisco experienced markedly favorable trends, whereas little change was observed for nonwhite gay men from nonurban areas. AIDS incidence trends were quantitatively consistent with the fraction of AIDS-free persons with severe immunodeficiency who received zidovudine in three cohorts. Gay men in San Francisco used zidovudine more frequently than did adults with hemophilia, while little was used by intravenous drug users in New York City. Data describing the initial national distribution of zidovudine (March 31-September 18, 1987) indicated relatively high use by patients with severe immunodeficiency in those groups, such as urban white gay men, that subsequently experienced fewer cases of AIDS than expected. Available data suggest that zidovudine, perhaps in combination with other therapies, has been one factor contributing to favorable AIDS incidence trends in some groups. Broader application of therapy might further retard the incidence of AIDS, especially in intravenous drug users, persons infected through heterosexual contact, minorities, women, and persons diagnosed outside major metropolitan areas.

AB - After mid-1987 fewer than the expected number of cases of AIDS were reported in the United States in some demographic and transmission groups but not in others. Gay men (regardless of intravenous drug use), adults with hemophilia, and transfusion recipients exhibited fewer cases than expected based on previously reliable models. These favorable trends could not be explained by assuming earlier cessation of human immunodeficiency virus (HIV) infection. Favorable AIDS incidence trends were not found in heterosexual intravenous drug users or in persons infected through heterosexual contact. White gay men from New York City, Los Angeles, and San Francisco experienced markedly favorable trends, whereas little change was observed for nonwhite gay men from nonurban areas. AIDS incidence trends were quantitatively consistent with the fraction of AIDS-free persons with severe immunodeficiency who received zidovudine in three cohorts. Gay men in San Francisco used zidovudine more frequently than did adults with hemophilia, while little was used by intravenous drug users in New York City. Data describing the initial national distribution of zidovudine (March 31-September 18, 1987) indicated relatively high use by patients with severe immunodeficiency in those groups, such as urban white gay men, that subsequently experienced fewer cases of AIDS than expected. Available data suggest that zidovudine, perhaps in combination with other therapies, has been one factor contributing to favorable AIDS incidence trends in some groups. Broader application of therapy might further retard the incidence of AIDS, especially in intravenous drug users, persons infected through heterosexual contact, minorities, women, and persons diagnosed outside major metropolitan areas.

KW - Access to health care

KW - AIDS incidence

KW - Backcalculation

KW - Human immunodeficiency virus

KW - Zidovudine

UR - http://www.scopus.com/inward/record.url?scp=0026064271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026064271&partnerID=8YFLogxK

M3 - Article

C2 - 2007974

AN - SCOPUS:0026064271

VL - 4

SP - 392

EP - 401

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 4

ER -